Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Burkitt Lymphoma
- CD20+ Lymphoblastic Lymphoma
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma, Grade III
- Non Hodgkin Lymphoma
- Primary Mediastinal B Cell Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 3 years and 31 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02393157
- Collaborators
- Roswell Park Cancer Institute
- Investigators
- Study Chair: Mitchell Cairo, MD New York Medical College Principal Investigator: Matthew Barth, MD Roswell Park Cancer Institute
Get Well Soon